Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

404.46 -10.75 (-2.59%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
20 21 Next >
News headline image
Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Top Biotech Picks For 2024: Piper Sandler Foresees Potential Sector Comeback ↗
Piper Sandler sees potential turnaround for Biotech sector in 2024, identifies thee top stocks; Arrowhead, Legend Biotech & Alnylam Pharmaceuticals. 
Via Benzinga
News headline image
Pricing Projections And Market Potential For Ionis' Newly Approved Nerve Damage Drug - Analyst Sees Over $700M Potential ↗
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) for polyneuropathy (nerve damage) of hereditary transthyretin-mediated am 
Via Benzinga
News headline image
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Analyst Expectations for Alnylam Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Expert Ratings for Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
3 biotech powerhouses poised to thrive amid sector rebound
If the newfound support and uptrend in the biotech sector last, as the new year quickly approaches, the biotech sector could shift from lagger to leader. 
Via MarketBeat
Topics ETFs
News headline image
Alnylam to Webcast Virtual R&D Day
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why Newly Listed Korro Bio Shares Are Gaining Today ↗
H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases. 
Via Benzinga
News headline image
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Outlook For Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Expert Ratings for Alnylam Pharmaceuticals ↗
 
Via Benzinga
News headline image
Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shareholder Alert: Investigation over Possible Violations of Securities Laws ↗
San Diego, CA -- (SBWIRE) -- 11/08/2023 -- Alnylam Pharmaceuticals, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Recognized by Science Magazine as Top Employer for Fifth Consecutive Year
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Third Quarter 2023 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗
The company can begin a pivotal study of its treatment for cardiomyopathy. 
Via Investor's Business Daily
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023 ↗
 
Via Benzinga
News headline image
CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in... 
Via Benzinga
News headline image
Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today? ↗
The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin- 
Via Benzinga
News headline image
Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug ↗
Shares skidded to their lowest point since September on the FDA's rejection. 
Via Investor's Business Daily
News headline image
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
2 Growth Stocks That Could Rocket Higher Before the End of 2023 ↗
Potential approvals of new medicines expected soon could push these stocks through the roof. 
Via The Motley Fool
News headline image
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis, Including 24-Month Results From the APOLLO-B Phase 3 Study, at the Heart Failure Society of America Annual Scientific Meeting 2023
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.